145 related articles for article (PubMed ID: 36301939)
1. In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization.
Ejaz SA; Saeed A; Birmani PR; Katubi KM; Elqahtani ZM; Al-Buriahi MS; Ujan R; Siddique F; Ahmed SB; Alrowaili ZA
PLoS One; 2022; 17(10):e0271602. PubMed ID: 36301939
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract][Full Text] [Related]
4. New Insight into the Pharmacological Importance of Atropine as the Potential Inhibitor of AKR1B1 via Detailed Computational Investigations: DFTs, ADMET, Molecular Docking, and Molecular Dynamics Studies.
Ejaz SA; Aziz M; Ahmed A; Alotaibi SS; Albogami SM; Siddique F; Batiha GE
Appl Biochem Biotechnol; 2023 Aug; 195(8):5136-5157. PubMed ID: 36847982
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive computational approach for the identification of structure-based potential pharmacological candidates as selective AKR1B1 and AKR1B10 inhibitors: repurposing of purine alkaloids for the treatment of cancer.
Aziz M; Ejaz SA; Tamam N; Siddique F
J Biomol Struct Dyn; 2023; 41(16):7892-7912. PubMed ID: 36214620
[TBL] [Abstract][Full Text] [Related]
6. Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition.
Liu M; Qin X; Li J; Jiang Y; Jiang J; Guo J; Xu H; Wang Y; Bi H; Wang Z
Phys Chem Chem Phys; 2024 Mar; 26(12):9295-9308. PubMed ID: 38469695
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
11. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
14. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of (R)-(6-Methoxyquinolin-4-yl)[(1S,2S,4S,5R)-5-vinylquinuclidin-2-yl]methanol Tetraphenylborate Ion-Pair Complex: Characterization, Antimicrobial, and Computational Study.
Yousef TA; Alrabiah H; Al-Agamy MH; Al-Salahi R; Ali EA; Mostafa GAE
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836825
[TBL] [Abstract][Full Text] [Related]
18. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
20. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
